Skip Navigation

Annals of Oncology 2007 18(7):1127; doi:10.1093/annonc/mdm396
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in Ann Oncol
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

in this issue

In this issue

The first 10% of the full text of this article appears below.


   Oral ibandronate versus intravenous zoledronic acid
 
Bisphosphonates such as clodronate, ibandronate, pamidronate and zoledronic acid are the standard of care for patients with metastatic bone disease. Biochemical markers of bone resorption show potential in the initial evaluation of bone metastases, as surrogates of disease progression, as fracture predictors, and as prognostic factors of survival. In addition, serum levels of biochemical markers of bone cell activity are increasingly recognized as useful determinants for assessing the clinical response to antineoplastic and . . . [Full Text of this Article]


   FOLFOX, bevacizumab and erlotinib for metastastic colorectal cancer
 

   Phase I/II Study of galiximab with rituximab
 

   Effects of chemotherapy on reactivation of tuberculosis
 

   Quote
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in Ann Oncol:

Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases
J-J Body, M Lichinitser, S Tjulandin, P Garnero, and B Bergström
Ann Oncol 2007 18: 1165-1171. [Abstract] [Full Text]  

Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastastic colorectal cancer
JA Meyerhardt, K Stuart, CS Fuchs, AX Zhu, CC Earle, P Bhargava, L Blaszkowsky, P Enzinger, RJ Mayer, S Battu, C Lawrence, and DP Ryan
Ann Oncol 2007 18: 1185-1189. [Abstract] [Full Text]  

A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma
JP Leonard, JW Friedberg, A Younes, D Fisher, LI Gordon, J Moore, M Czuczman, T Miller, P Stiff, BD Cheson, A Forero-Torres, N Chieffo, B McKinney, D Finucane, and A Molina
Ann Oncol 2007 18: 1216-1223. [Abstract] [Full Text]  

The effect of short-term intensive chemotherapy on reactivation of tuberculosis
R Nair, K Prabhash, M Sengar, A Bakshi, S Gujral, S Gupta, and P Parikh
Ann Oncol 2007 18: 1243-1245. [Abstract] [Full Text]